is retatrutide on the market yet Retatrutide, an experimental weight-loss drug, has not been approved by FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation We're excited to share that

Metabolic health profile

Medical Disclaimer: This content is for informational and educational purposes only

Use With Caution in Research Contexts Because Retatrutide interacts with GLP-1, GIP, and glucagon receptor pathways involved in metabolism, appetite regulation, gastric-emptying pathways, and glucose signaling, additional caution may be warranted in research models involving significant metabolic, gastrointestinal, pancreatic, or cardiometabolic conditions

Mistake #2: Eating High-Fat Breakfast Meats Why it's a problem: GLP-1 medications slow gastric emptying, and high-fat foods sit in your stomach even longer

Clinical trials have shown that Retatrutide is generally well-tolerated with a safety profile similar to other GLP-1 medications

GLP-1 microdosing uses sub-therapeutic doses (0.05-0.25mg semaglutide weekly vs standard 0.25-2.4mg) to minimize gastrointestinal side effects while achieving mild appetite suppression